Inclusion Criteria:

          1. Newly diagnosed histologically proven supratentorial GBM

          2. Tumor tissue specimens from the GBM surgery or open biopsy must be available for MGMT
             gene promoter status analysis and central pathology review.

          3. Documented unmethylated MGMT gene promoter status

          4. Males or females ≥18< 70 years of age.

          5. Interval of ≥2 weeks but ≤7 weeks after surgery or biopsy before first administration
             of study treatment.

          6. Cranial MRI must have been performed within 21 days of study entry and MRI must be
             used throughout the period of protocol treatment for tumor measurement. If the
             surgical procedure was a resection, cranial MRI performed within 72 hours of resection
             is preferred

          7. Stable or decreasing dose of steroids for ≥5 days prior to randomization.

          8. Karnofsky performance score ≥ 70%

          9. Patients must begin treatment with VAL-083 chemotherapy no sooner than 2 weeks and no
             later than 4 weeks from the diagnostic surgery.

         10. ANC ≥1,500/ µl

         11. Platelet count ≥ 100,000/µl

         12. Hemoglobin ≥ 10 gm/dl

         13. AST, ALT < 2.5 times ULN

         14. Bilirubin < 2.5 ULN

         15. Serum creatinine ≤ 1.5x ULN or creatinine clearance > 50 mL/min (measured or
             calculated by the Cockcroft-Gault formula) (Cockcroft, 1976) at screening

        Exclusion Criteria:

          1. Prior chemotherapy within the last 5 years.

          2. Prior radiation therapy of the head.

          3. Receiving concurrent investigational agents or has received an investigational agent
             within the past 30 days prior to the first dose of VAL-083.

          4. Prior systemic anti-angiogenic therapy.

          5. Placement of Gliadel® wafer at surgery.

          6. Planned surgery for other diseases (e.g. dental extraction).

          7. History of recent peptic ulcer disease (endoscopically proven gastric ulcer, duodenal
             ulcer, or esophageal ulcer) within 6 months of enrollment.

          8. History of malignancy. Subjects with curatively treated cervical carcinoma in situ or
             basal cell carcinoma of the skin, or subjects who have been free of other malignancies
             for ≥5 years are eligible for this study.

          9. History of coagulation disorder associated with bleeding or recurrent thrombotic
             events.

         10. Clinically manifest myocardial insufficiency (New York Heart Association [NYHA] III,
             IV) or history of myocardial infarction during the past 6 months; or uncontrolled
             arterial hypertension.

         11. Inability to undergo Gd-MRI.

         12. Concurrent illness, including severe infection, which may jeopardize the ability of
             the subject to receive the procedures outlined in this protocol with reasonable
             safety.

         13. Subject is pregnant (positive serum beta human chorionic gonadotropin [b-HCG] test at
             screening) or is currently breast-feeding, anticipates becoming pregnant/ impregnating
             their partner during the study or within 6 months after study participation, or
             subject does not agree to follow acceptable methods of birth control, such as hormonal
             contraception, intra-uterine pessar, condoms or sterilization, to avoid conception
             during the study and for at least 6 months after receiving the last dose of study
             treatment.

         14. Current alcohol dependence or drug abuse.

         15. Known hypersensitivity to the study treatment.

         16. Legal incapacity or limited legal capacity.

         17. Presence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

         18. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family
             members who suffer(ed) from such.